Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

BACKGROUND: Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility and is not used in routine clinical practice....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tian, Pabla, Sarabjot, Lenzo, Felicia L., Conroy, Jeffrey M., Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Giamo, Vincent, Andreas, Jonathan, Wang, Yirong, Bshara, Wiam, Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Gupta, Rajan, Zhu, Jason, Labriola, Matthew, McCall, Shannon, George, Daniel J., Ghatalia, Pooja, Dayyani, Farshid, Edwards, Robert, Park, Michelle S, Singh, Rajbir, Jacob, Robin, George, Saby, Xu, Bo, Zibelman, Matthew, Kurzrock, Razelle, Morrison, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458647/
https://www.ncbi.nlm.nih.gov/pubmed/32923131
http://dx.doi.org/10.1080/2162402X.2020.1773200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458647/
https://www.ncbi.nlm.nih.gov/pubmed/32923131
http://dx.doi.org/10.1080/2162402X.2020.1773200

Ejemplares similares